Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Equal-Weight rating on Bristol-Myers Squibb (NYSE:BMY) and lowers the price target from $65 to $64.
July 11, 2023 | 10:24 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays has maintained an Equal-Weight rating on Bristol-Myers Squibb and lowered the price target from $65 to $64.
The news is directly related to Bristol-Myers Squibb as Barclays has maintained its rating and adjusted the price target. This could potentially influence investor sentiment and the stock's price, but the impact is neutral as the rating remains unchanged and the price target is only slightly lowered.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100